Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2026-05-18 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
北京国枫律师事务所关于中源协和细胞基因工程股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter from a law firm on the legality of convening and conducting the company’s 2025 Annual General Meeting, and it provides the detailed vote counts and results for each resolution. It serves to officially declare and verify shareholder voting outcomes. This aligns with the “Declaration of Voting Results & Voting Rights Announcements” category (Code: DVA).
2026-05-18 Chinese
中源协和细胞基因工程股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the 2025 annual general shareholders’ meeting resolutions, detailing attendance and vote counts/results for each proposal (board elections, profit distribution, compensation plans, etc.). It provides official voting results from the AGM. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-18 Chinese
中源协和细胞基因工程股份有限公司十二届一次临时董事会会议决议公告
Board/Management Information Classification · 92% confidence The document is an announcement of board meeting resolutions of the company’s 12th interim board of directors meeting, detailing election of board chairman, vice chairmen, committee memberships, and multiple senior management appointments. It is clearly a Board/Management Information filing.
2026-05-18 Chinese
中源协和细胞基因工程股份有限公司关于召开2025年年度股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 84% confidence The document is a formal “Notice of the 2025 Annual General Meeting” including meeting date, location, agenda items, voting procedures, proxy form (Attachment 1), and cumulative voting instructions (Attachment 2), all of which are information and solicitation materials sent to shareholders in advance of a shareholder meeting. This fits the “Proxy Solicitation & Information Statement” category rather than the report itself or voting results.
2026-05-12 Chinese
中源协和细胞基因工程股份有限公司2025年年度股东会会议资料
Regulatory Filings
2026-05-08 Chinese
中源协和细胞基因工程股份有限公司董事会审计委员会对会计师事务所履行监督职责情况报告
Regulatory Filings
2026-04-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.